142 related articles for article (PubMed ID: 23992277)
1. Erythema nodosum, a "red flag" during anti-TNF therapy.
Dalmau-Carolà J
Int J Rheum Dis; 2013 Aug; 16(4):493-4. PubMed ID: 23992277
[No Abstract] [Full Text] [Related]
2. Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis.
Bougea A; Anagnostou E; Stamboulis E; Kararizou E
Rev Neurol (Paris); 2014 Mar; 170(3):228-9. PubMed ID: 24656415
[No Abstract] [Full Text] [Related]
3. Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series.
Sadlier M; Lally A; Kirby B
Br J Dermatol; 2012 Oct; 167(4):937-8. PubMed ID: 22428935
[No Abstract] [Full Text] [Related]
4. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
[No Abstract] [Full Text] [Related]
5. Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis.
Guidelli GM; Tenti S; Fioravanti A
Indian J Dermatol Venereol Leprol; 2014; 80(2):187-9. PubMed ID: 24685874
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
7. Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-α antagonists: implications for management?
Teh BW; Street AC; McBryde ES; Denholm JT
J Rheumatol; 2012 Jun; 39(6):1297-8. PubMed ID: 22661422
[No Abstract] [Full Text] [Related]
8. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
9. Tuberculosis after anti-TNF therapy: a continuous learning process.
Psichogiou M; Sfikakis PP; Kontos F; Daikos GL
Scand J Rheumatol; 2012 Oct; 41(5):401-3. PubMed ID: 22803620
[No Abstract] [Full Text] [Related]
10. Endometrium cancer in a female with psoriatic arthritis treated with TNF alpha antagonist adalimumab.
Erten S
Rheumatol Int; 2011 Nov; 31(11):1537-8. PubMed ID: 21120492
[No Abstract] [Full Text] [Related]
11. Ustekinumab for resistant psoriatic arthritis.
Wallis DE; Waldron NM; Korendowych E
J Rheumatol; 2013 Feb; 40(2):207. PubMed ID: 23378500
[No Abstract] [Full Text] [Related]
12. Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?
Orr C; Veale DJ
Ann Rheum Dis; 2014 Jun; 73(6):951-3. PubMed ID: 24790066
[No Abstract] [Full Text] [Related]
13. Alopecia areata during treatment with adalimumab: therapy with an alternative TNF-alpha inhibitor is possible.
Zschoche C; Bidier M; Hadaschik E
J Dtsch Dermatol Ges; 2013 May; 11(5):450-3. PubMed ID: 23279686
[No Abstract] [Full Text] [Related]
14. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient.
Lindsey SF; Weiss J; Lee ES; Romanelli P
J Drugs Dermatol; 2014 Jul; 13(7):869-71. PubMed ID: 25007373
[TBL] [Abstract][Full Text] [Related]
15. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
[TBL] [Abstract][Full Text] [Related]
17. Therapy: Ustekinumab after anti-TNF failure: a step closer to the PSUMMIT of psoriatic arthritis therapy?
Onuora S
Nat Rev Rheumatol; 2014 Mar; 10(3):125. PubMed ID: 24535545
[No Abstract] [Full Text] [Related]
18. Alopecia areata universalis elicited during treatment with adalimumab.
Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-α inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis.
Nishimura K; Saegusa J; Kawano S; Morinobu A
J Rheumatol; 2012 Sep; 39(9):1904-5. PubMed ID: 22942311
[No Abstract] [Full Text] [Related]
20. Late onset tuberculosis infection in patients receiving anti-TNFα therapy.
Mongey AB; Doran JP; Kleinerova J; Fitzgerald O; McDonnell TJ
QJM; 2014 Jan; 107(1):69-71. PubMed ID: 23970181
[No Abstract] [Full Text] [Related]
[Next] [New Search]
